



# OZEMPIC/GLP-1 RA LAWSUITS

Levin Papantonio is representing clients who took Ozempic and other GLP-1 RA class drugs and have suffered Gastroparesis, Stomach Paralysis, Gastric Obstruction, or Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).



**LEVIN PAPANTONIO**

PROCTOR | BUCHANAN | O'BRIEN  
BARR | MOUGEY | P.A.


# THE LITIGATION OZEMPIC/GLP-1 RA

---

Ozempic and other GLP-1 Receptor Agonist drugs are a class of medications used to control high blood sugar in individuals with type 2 diabetes mellitus. These medications mimic a natural human glucagon-like peptide (GLP-1) to slow the passing of food through the stomach and are now also prescribed for weight loss.

These drugs have been linked to several dangerous and potentially permanent medical conditions, including gastroparesis—a condition in which the stomach does not empty properly—and non-arteritic anterior ischemic optic neuropathy (NAION), a serious eye disorder that can lead to sudden vision loss. In a healthy individual, strong stomach muscles contract to move food through the digestive tract. In patients with gastroparesis, this motility slows down or stops altogether, often requiring medical intervention or surgery. NAION, meanwhile, results from reduced blood flow to the optic nerve and may cause irreversible damage to vision.

Lawsuits allege that the manufacturers of these drugs knew about these serious risks and failed to adequately warn patients and healthcare providers.



# HOW ARE OZEMPIC, WEGOVY, AND RYBELSUS USED?

---

Ozempic, Wegovy, and Rybelsus belong to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RA). All three drugs share the same common active ingredient: semaglutide.

## THE SEMAGLUTIDE CLASS

Semaglutide is a class of prescription drug used to control high blood sugar in individuals with type 2 diabetes mellitus. It is classified as a GLP-1 Receptor Agonist Analog-Type drug. The medication mimics a natural human glucagon-like peptide (GLP-1) to slow the passing of food through the stomach.

## HOW THE WEIGHT-LOSS DRUGS DIFFER

Patients receive Ozempic and Wegovy as a subcutaneous injection. The key difference between the two drugs is that Ozempic is designed for treatment of type 2 diabetes at doses of 0.5 to 1 mg weekly, while Wegovy has been FDA-approved as a weight loss drug with a weekly dosage of 2.4 mg. Like Ozempic, Rybelsus is designed to treat type 2 diabetes mellitus, but the patient takes this medication daily in the form of an oral tablet.

## WHAT IS GASTROPARESIS/STOMACH PARALYSIS?

---

Gastroparesis is a medical condition in which the patient's stomach does not empty properly. According to Mayo Clinic, strong muscles in a healthy stomach contract to move food through the digestive tract. The motility in a patient with gastroparesis, however, slows down. In some cases, the muscles do not work at all.

As a result, the patient's stomach does not empty—or fails to empty to the extent it should—meaning food stays in the stomach longer than it should, rather than moving on for digestion in the small intestine.

# WHAT ARE THE SIGNS AND SYMPTOMS OF GASTROPARESIS/STOMACH PARALYSIS?

---

Gastroparesis can negatively impact a patient's blood sugar levels and nutrition. The condition can also impede healthy digestion. Symptoms of gastroparesis include:

- Nausea • Vomiting • Bloating of the abdomen • Abdominal pain • Feeling full after eating very little • Alterations in blood sugar levels • Acid reflux • Malnutrition • Weight loss • Loss of appetite

# WHAT IS THE TREATMENT FOR GASTROPARESIS/STOMACH PARALYSIS?

---

There is no cure for gastroparesis. Treatments for the condition appear to offer only temporary benefits, according to MedlinePlus, the authoritative source that gathers health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

# WHAT IS NAION?

---

Non-arteritic anterior ischemic optic neuropathy (NAION) is a serious medical condition that affects the optic nerve and can lead to sudden, often permanent vision loss. According to the Mayo Clinic and other medical sources, NAION occurs when blood flow to the optic nerve is reduced or blocked, typically without inflammation. The optic nerve is responsible for transmitting visual information from the eye to the brain, and when it does not receive enough oxygen-rich blood, nerve tissue can become damaged.

In patients with NAION, this damage can cause partial or complete vision loss in one eye, often occurring without warning and without pain. There is currently no proven treatment to reverse vision loss caused by NAION, making early detection and risk awareness critical.

# WHAT SPECIFIC CLAIMS ARE CURRENTLY BEING FILED?

---

Our law firm is currently investigating cases on behalf of individuals who received Ozempic, Rybelsus, or Wegovy brand GLP-1 RA treatments (in pills or via injections) and:

- Are 75 years of age or younger; and
- Received a diagnosis of gastroparesis, stomach paralysis, gastric obstruction, or non-arteritic anterior ischemic optic neuropathy (NAION) while taking these drugs or within 30 days of stopping use; and
- Required an emergency room visit or hospital admission.

Since its founding in 1955, Levin Papantonio has developed extensive litigation expertise, securing verdicts and settlements in excess of \$80 billion. We have served in leadership roles in over 75 Multi-District Litigations (MDLs) and have earned a place in the Best Law Firms by U.S. News & World Report. Our legacy includes recognition in the National Trial Lawyers Hall of Fame, and we proudly finance all costs associated with case referrals, ensuring that our partners and clients are fully supported throughout the legal process.

Levin Papantonio is deeply committed to pursuing justice in the Ozempic / GLP-1 RA lawsuits, working tirelessly to hold responsible parties accountable. We welcome the opportunity to work together on this important litigation, combining our strengths to better serve clients and achieve the best possible outcomes. By collaborating, we can leverage our collective resources and expertise to fight for those affected, with the shared goal of delivering meaningful results.



**Cameron Stephenson**  
Shareholder  
Plaintiffs' Executive Committee  
[cstephenson@levinlaw.com](mailto:cstephenson@levinlaw.com)



**Matthew Marcin**  
Attorney  
[mmarcin@levinlaw.com](mailto:mmarcin@levinlaw.com)

**If you would like additional information or interested in a co-counsel relationship, please contact our team at [glpgroup@levinlaw.com](mailto:glpgroup@levinlaw.com) or call (800) 277-1193.**



# LEVIN PAPANTONIO

---

PROCTOR | BUCHANAN | O'BRIEN  
BARR | MOUGEY | P.A.

[www.levinlaw.com](http://www.levinlaw.com)